SARS-CoV-2-Induced Remission of Chemotherapy Resistance B-Cell Non-Hodgkin Lymphoma: A Case Report

Yan Xiao; Jinwei Wang; Kai Yang; Meiling Jiang; Bo Zhang

doi:10.1159/000541964

Case Reports in Oncology (Nov 2024)

SARS-CoV-2-Induced Remission of Chemotherapy Resistance B-Cell Non-Hodgkin Lymphoma: A Case Report

Yan Xiao,
Jinwei Wang,
Kai Yang,
Meiling Jiang,
Bo Zhang

Affiliations

Yan Xiao: Respiratory Infection and Critical Disease Diagnosis and Treatment, Beijing Gobroad Boren Hospital, Beijing, China
Jinwei Wang: Respiratory Infection and Critical Disease Diagnosis and Treatment, Beijing Gobroad Boren Hospital, Beijing, China
Kai Yang: Respiratory Infection and Critical Disease Diagnosis and Treatment, Beijing Gobroad Boren Hospital, Beijing, China
Meiling Jiang: Respiratory Infection and Critical Disease Diagnosis and Treatment, Beijing Gobroad Boren Hospital, Beijing, China
Bo Zhang: Respiratory Infection and Critical Disease Diagnosis and Treatment, Beijing Gobroad Boren Hospital, Beijing, China

DOI: https://doi.org/10.1159/000541964
Journal volume & issue: Vol. 17, no. 1
pp. 1273 – 1276

Abstract

Read online

Introduction: Investigation on virus-host interaction may provide new clues for antitumor immunotherapy. Case Presentation: In this case report, we describe an unusual case of B-cell non-Hodgkin lymphoma in an aged woman who recovered following SARS-COV-2 infection. We discuss the case and suggest that virus induced cross-reactivity against tumor account for the remission. Conclusion: Mapping epitope characteristics on B cell non-Hodgkin lymphoma antigen and on SARS-COV-2 antigen may provide much needed information for antigen based antitumor immune therapy in the future.

Published in Case Reports in Oncology

ISSN: 1662-6575 (Online)
Publisher: Karger Publishers
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.karger.com/cro

About the journal

Abstract

Keywords